Lineage Cell Therapeutics Stock Price and Value Analysis

Should you buy Lineage Cell Therapeutics stock? (NYSE American:BTX). Let's see how it does in our automated value investing analysis system.

  • This company has amazingly consistent growth!
  • This company is solid.
  • This stock looks overpriced.
  • This company is not making money.
  • This company pays no dividend.

Inside the BTX Numbers

BTX Price
(Lineage Cell Therapeutics stock price per share)
[?] PE Ratio versus Sector 80% lower than other Unknown stocks
[?] PE Ratio versus Industry 93% lower than other Unknown stocks
[?] Cash Yield -16.35%
[?] Free Cash Flow Jitter 11%

Is Lineage Cell Therapeutics Stock on Sale?

Based on our analysis, we believe that you should not buy Lineage Cell Therapeutics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy BTX Stock?

Does Lineage Cell Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.